Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimodivir TQT study in healthy subjects
NCT02658825Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2016
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pimodivir in Influenza A (IAV) (8 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change From Baseline in Corrected QT Interval at Day 1. Started Jan 2016; status: completed.
02
Drugs
pimodivir
03
Conditions
Influenza A (IAV)
Beyond the preview
Go deeper on NCT02658825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02658825.